Phathom Pharmaceuticals, Inc. (PHAT) DCF Valuation

Valoración de DCF Phathom Pharmaceuticals, Inc. (PHAT)

US | Healthcare | Biotechnology | NASDAQ
Phathom Pharmaceuticals, Inc. (PHAT) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Phathom Pharmaceuticals, Inc. (PHAT) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Descubra el verdadero potencial de Phathom Pharmaceuticals, Inc. (PHAT) con nuestra calculadora DCF avanzada! Ajuste los supuestos clave, explore varios escenarios y evalúe cómo los cambios afectan la valoración de Phathom, todo dentro de una sola plantilla de Excel.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .7 .7 .7 .7 .7 .7
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -250.9 -124.2 -134.6 -171.8 -159.0 .4 .4 .4 .4 .4
EBITDA, % 100 100 100 100 -23320.97 60 60 60 60 60
Depreciation .0 .3 .5 .6 .6 .7 .7 .7 .7 .7
Depreciation, % 100 100 100 100 84.31 96.86 96.86 96.86 96.86 96.86
EBIT -251.0 -124.5 -135.1 -172.4 -159.6 .4 .4 .4 .4 .4
EBIT, % 100 100 100 100 -23405.28 60 60 60 60 60
Total Cash 243.8 287.5 183.3 155.4 381.4 .7 .7 .7 .7 .7
Total Cash, percent .0 .0 .0 .0 .1 .0 .0 .0 .0 .0
Account Receivables .0 .1 .0 .0 1.6
Account Receivables, % 100 100 100 100 240.03
Inventories .0 -.1 .0 .0 1.2 .7 .7 .7 .7 .7
Inventories, % 100 100 100 100 177.13 100 100 100 100 100
Accounts Payable .7 16.8 5.2 10.0 12.6 .7 .7 .7 .7 .7
Accounts Payable, % 100 100 100 100 1847.65 100 100 100 100 100
Capital Expenditure -25.3 -1.0 -.3 -1.0 -1.6 -.1 -.1 -.1 -.1 -.1
Capital Expenditure, % 100 100 100 100 -239.59 -20 -20 -20 -20 -20
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -206.3 -128.6 -139.0 -194.5 -159.6 .4 .4 .4 .4 .4
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -230.9 -113.2 -150.5 -190.1 -160.9 -9.5 .9 .9 .9 .9
WACC, % 12.06 13.4 13.4 13.4 13.4 13.13 13.13 13.13 13.13 13.13
PV UFCF
SUM PV UFCF -6.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 1
Terminal Value 8
Present Terminal Value 5
Enterprise Value -1
Net Debt -242
Equity Value 241
Diluted Shares Outstanding, MM 51
Equity Value Per Share 4.70

What You Will Get

  • Pre-Filled Financial Model: Phathom Pharmaceuticals’ actual data enables precise DCF valuation.
  • Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers tailored for [PHAT].
  • Instant Calculations: Automatic updates ensure you see results as you make changes to your [PHAT] model.
  • Investor-Ready Template: A refined Excel file designed for professional-grade valuation of [PHAT].
  • Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts on [PHAT].

Key Features

  • Customizable Financial Metrics: Adjust essential inputs such as revenue projections, R&D spending, and operational costs.
  • Instant DCF Valuation: Quickly computes intrinsic value, net present value, and additional financial metrics.
  • High-Precision Analysis: Incorporates Phathom Pharmaceuticals’ actual financial data for accurate valuation results.
  • Streamlined Scenario Testing: Easily evaluate various assumptions and analyze different outcomes.
  • Efficiency Booster: Remove the hassle of creating intricate valuation models from the ground up.

How It Works

  • Download: Access the ready-to-use Excel file with Phathom Pharmaceuticals' (PHAT) financial data.
  • Customize: Adjust forecasts, including revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations update in real-time.
  • Test Scenarios: Create multiple projections and compare outcomes instantly.
  • Make Decisions: Use the valuation results to guide your investment strategy.

Why Choose Phathom Pharmaceuticals, Inc. (PHAT)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
  • Proven Expertise: A team of experienced professionals dedicated to advancing healthcare.
  • Robust Pipeline: A diverse range of products in various stages of development.
  • Commitment to Quality: Adherence to the highest standards in research and production.
  • Positive Impact: Focused on improving patient outcomes and quality of life.

Who Should Use This Product?

  • Healthcare Investors: Construct comprehensive and accurate valuation models for portfolio assessments related to Phathom Pharmaceuticals, Inc. (PHAT).
  • Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the pharmaceutical sector.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in Phathom Pharmaceuticals, Inc. (PHAT).
  • Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling within the biotech industry.
  • Pharma Enthusiasts: Gain insights into how companies like Phathom Pharmaceuticals, Inc. (PHAT) are valued in the healthcare market.

What the Template Contains

  • Preloaded PHAT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.